AbbVie (ABBV) is one of the more controversial dividend aristocrats for several reasons. As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats.   The bigger challenge, however, is AbbVie’s profit drivers. Most dividend aristocrats possess the characters we desire when searching for safe dividend stocks. [...]